Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ACRV 
Acrivon Therapeutics, Inc. Common Stock (ACRV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: ACRV (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
9 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $11.17
1 Year Target Price $11.17
| 4 | Strong Buy |
| 4 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -51.41% | Avg. Invested days 21 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 48.76M USD | Price to earnings Ratio - | 1Y Target Price 11.17 |
Price to earnings Ratio - | 1Y Target Price 11.17 | ||
Volume (30-day avg) 9 | Beta 1.67 | 52 Weeks Range 1.05 - 8.74 | Updated Date 09/17/2025 |
52 Weeks Range 1.05 - 8.74 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.24 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -30.32% | Return on Equity (TTM) -47.88% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -85403751 | Price to Sales(TTM) - |
Enterprise Value -85403751 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.43 | Shares Outstanding 31455600 | Shares Floating 16683445 |
Shares Outstanding 31455600 | Shares Floating 16683445 | ||
Percent Insiders 20.64 | Percent Institutions 56.75 |
Upturn AI SWOT
Acrivon Therapeutics, Inc. Common Stock
Company Overview
History and Background
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancer patients. Founded in 2009, it aims to transform cancer drug development by leveraging its proprietary proteomics-based drug discovery platform, Acrivon Predictive Precision (APrism).
Core Business Areas
- Drug Development: Focuses on developing oncology therapeutics by identifying drug candidates that specifically target cancer-driving proteins.
- Acrivon Predictive Precision (APrism) Platform: A proprietary platform that enables the discovery and development of new cancer therapies by identifying responders to specific drugs.
- Clinical Trials: Conducting clinical trials to evaluate the safety and efficacy of its drug candidates in cancer patients.
Leadership and Structure
Dr. Peter Blume-Jensen is the President and CEO. The company has a board of directors overseeing strategic direction and a management team responsible for day-to-day operations. The structure includes research, clinical development, and commercial functions.
Top Products and Market Share
Key Offerings
- ACrivon's lead product candidate, ACR-368: ACR-368 is a Chk1/2 inhibitor being developed for cancers with DNA damage repair deficiencies. Market share data is not yet available as it is in clinical development. Competitors include companies developing other Chk1/2 inhibitors and DNA damage response inhibitors such as Repare Therapeutics (RPTX) and Artios Pharma.
Market Dynamics
Industry Overview
The oncology therapeutics market is large and competitive, driven by the increasing incidence of cancer and advancements in precision medicine. Targeted therapies and immunotherapies are key growth areas.
Positioning
Acrivon is positioned as a precision oncology company leveraging proteomics to develop targeted therapies. Its APrism platform differentiates it from traditional drug development approaches.
Total Addressable Market (TAM)
The global oncology market is estimated to reach hundreds of billions of dollars. Acrivon is positioned to capture a portion of this TAM by developing targeted therapies for specific cancer subtypes.
Upturn SWOT Analysis
Strengths
- Proprietary APrism platform
- Targeted approach to drug development
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Limited number of drug candidates in clinical development
- High dependence on the success of APrism platform
- Significant reliance on external funding
- Competition in the oncology therapeutics market
Opportunities
- Potential for breakthrough therapies
- Partnerships with larger pharmaceutical companies
- Expansion of APrism platform to other diseases
- Advancements in biomarker identification
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from established pharmaceutical companies
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- RPTX
- ARRY
- MRTX
- AZN
Competitive Landscape
Acrivon competes with established pharmaceutical companies and other biotech firms in the oncology space. Its APrism platform offers a potential competitive advantage in identifying responders to specific drugs.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by the progress of its drug development pipeline and the expansion of its APrism platform.
Future Projections: Future growth depends on clinical trial successes, regulatory approvals, and potential commercialization of its drug candidates.
Recent Initiatives: Recent strategic initiatives include advancing ACR-368 through clinical trials and expanding partnerships to leverage its APrism platform.
Summary
Acrivon Therapeutics is a clinical-stage biopharmaceutical company with a promising APrism platform for developing precision medicines in oncology. Its strength lies in its targeted approach and experienced team. However, it faces challenges related to clinical trial risks and competition in the crowded oncology market. Successful clinical trials and strategic partnerships will be crucial for its future growth.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Acrivon Therapeutics, Inc. Investor Relations
- SEC Filings
- Industry reports on oncology therapeutics
- Third-party financial data providers
Disclaimers:
The information provided is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a financial advisor. Market share estimates are approximate and subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Acrivon Therapeutics, Inc. Common Stock
Exchange NASDAQ | Headquaters Watertown, MA, United States | ||
IPO Launch date 2022-11-15 | Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 75 | Website https://acrivon.com |
Full time employees 75 | Website https://acrivon.com | ||
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.